Treatment Archives – Page 8 of 11 – Treatment Action Group

Treatment Action Group and the PrEP4All Collaboration Respond to Reported Remdesivir Results for COVID-19

April 30, 2020
Dorrit Walsh

Treatment Action Group (TAG) and the PrEP4All Collaboration welcome results from randomized controlled trials of therapies for COVID-19, but are seriously concerned about claims that data from a National Institutes of Allergy and Infectious Diseases (NIAID) study of the Gilead drug remdesivir...

An Activist’s Guide to Rifapentine for the Treatment of TB Infection

April 30, 2020
Chad Cipiti

The English version of this publication updated 2024. Please refer to the earlier versions on this page if you need languages other than English. English version updated April 2020. The updated guide reflects new information from recently completed clinical…

TAG Statement on WHO Updated TB Preventive Therapy Guidance

March 31, 2020
Dorrit Walsh

Last week, Treatment Action Group was pleased to receive the World Health Organization’s (WHO) update to its guidance on TB preventive therapy (TPT).

Treatment Action Group Statement on HIV Treatments and SARS-CoV-2/COVID-19

March 25, 2020
Dorrit Walsh

Treatment Action Group (TAG) is urging caution regarding the use of antiretroviral (ART) drugs as treatments for SARS-CoV-2/COVID-19. While there is clearly an acute need to carefully and quickly study interventions that may have activity against SARS-CoV-2, the virus which causes COVID-19 disease, it’s vitally important to be aware of the information that is currently available.

Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape

March 3, 2020
Dorrit Walsh

Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.

African Declaration to Eliminate Hepatitis C and Improve the Health of People Who Use Drugs

February 20, 2020
Dorrit Walsh

A group of organizations that includes Treatment Action Group issued this statement/declaration today, while attending INHSU 2020 Africa: the 1st Regional Conference on Hepatitis Care in Substance Users.

Responding to Difficult-to-Treat HCV Subtypes Prevalent in Sub-Saharan Africa

February 17, 2020
Dorrit Walsh

An issue brief that discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.

Statement from the ACT NOW:END AIDS Coalition on President Trump’s State of the Union Commitment to Eradicate AIDS

February 5, 2020
Dorrit Walsh

The ACT NOW:END AIDS Coalition, of which TAG is a founding member, released this statement today calling for the administration’s efforts to end the HIV epidemic to be rooted in fact, science, and sensible policies that are consistent with the stated goal of ending HIV.

Sanofi Withdraws Two Patent Applications on Life-Saving Tuberculosis Prevention Drugs in Europe and in Indonesia

January 22, 2020
Dorrit Walsh

Follow up to our 12/19 statement applauding Indian activists for taking legal action to oppose two patent applications filed by Sanofi in India. This joint statement from Treatment Action Group and OTMeds urges Sanofi to deliver on its promise to withdraw in all countries where the applications were filed and are still pending.

HIV & Aging

December 17, 2019
Chad Cipiti

A resource listing of articles, reports, websites, and ongoing clinical trials related to HIV and aging.